Moderna shares soared more than 172% after strong results for its vaccine for melanoma skin cancer. Elsewhere, the Evergrande ...

Moderna and Merck say Phase 3 trial results suggest their individualized mRNA vaccine can prevent melanoma from recurring or ...

A Moderna and Merck mRNA vaccine paired with Keytruda reduced melanoma recurrence or death risk by 49% over five years.

In addition to melanoma, Moderna and Merck are conducting trials with personalized injections to fight types of bladder, ...

Key Takeaways Experimental mRNA vaccine plus Keytruda kept melanoma from returning or spreading after surgery in high-risk ...

Patients are asking about the side effects of Moderna's melanoma cancer vaccine. Here's what trial data has shown so far.

Moderna declines after skyrocketing the previous session. Walmart falls as guidance fails to impress.

A breakthrough melanoma vaccine is making headlines. But can patients get it yet? Here's where FDA approval stands.

Stéphane Bancel, the CEO of Moderna, called the newly announced Phase 3 findings “a pivotal moment for the field of cancer ...

AI-powered personalized cancer vaccine shows promising melanoma trial results, highlighting software-driven advances in ...

A landmark trial success for Moderna and Merck's cancer vaccine has strengthened the case for Scancell Holdings PLC (AIM:SCLP, OTC:SCNLF, FRA:SCP), the immuno-oncology company developing a rival ...

Moderna and Merck's personalized mRNA cancer vaccine has achieved the first positive Phase 3 result of its kind.